ArticleCurrent oncology (Toronto, Ont.)2013
Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation.
Article in Current oncology (Toronto, Ont.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives.Journal of musculoskeletal & neuronal interactions · 2022Pooled it
- The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials.Journal of cancer research and clinical oncology · 2022Pooled it
- Bisphosphonates in multiple myeloma: an updated network meta-analysis.The Cochrane database of systematic reviews · 2017Pooled it
- State-of-the-art of multidisciplinary approach of bone metastasis-directed therapy: review and challenging questions for preparation of a GEMO practice guidelines.Cancer metastasis reviews · 2025Review
- Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.Blood research · 2025Review
- The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021Review
- Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.International journal of molecular sciences · 2019Review
- The interplay between mutant p53 and the mevalonate pathway.Cell death and differentiation · 2018Review
- Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2Cancer immunology, immunotherapy : CII · 2017Article
- Adipose, Bone, and Myeloma: Contributions from the Microenvironment.Calcified tissue international · 2017Review
- Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma.BoneKEy reports · 2015Review
- A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma.International journal of clinical and experimental medicine · 2015Article
- Immunological dysregulation in multiple myeloma microenvironment.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA growing body of evidence is demonstrating that the nitrogen-containing bisphosphonate zoledronic acid (zol) improves clinical outcomes in various cancer settings, including multiple myeloma. Those findings provided the rationale for conducting an open-label randomized controlled phase iii trial to evaluate the effect of zol on overall survival (os) and progression-free survival (pfs) in patients with previously untreated high-risk multiple myeloma.
methodsThe trial randomly assigned 308 adult patients less than 65 years of age with previously untreated symptomatic multiple myeloma (1:1) to receive zol 4 mg intravenously once every 28 days for 24 months (n = 151) or no zol (n = 157). Before autologous stem-cell transplantation (asct), all patients received a high-dose noncytotoxic induction regimen of dexamethasone, all-trans-retinoic acid, and interferon alpha 2b.
resultsAfter a median follow-up of 69.8 months (range: 36.5-96 months), the 10-year pfs (66% vs. 52%, p < 0.001) and os (67% vs. 48%, p < 0.001) rates were significantly higher in treated patients than in control patients. Overall response (77% zol vs. 75% control), complete response (52% vs. 46%), and very good partial response (25% vs. 29%) rates were similar between the groups. Treatment was generally well tolerated, with no reports of renal impairment or osteonecrosis of the jaw.
conclusionsIn symptomatic previously untreated multiple myeloma patients, zol combined with high-dose therapy followed by asct improved os and pfs without appreciable toxicity. These findings provide additional evidence of the meaningful anticancer activity of zol in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.